Objective Pernicious anemia (PA) is an autoimmune disease that causes achlorhydria or profound hypochlorhydria. We conducted a population-based study to determine whether individuals with PA are at an increased risk for community-acquired pneumonia (CAP). Methods We performed a retrospective cohort study using The Health Improvement Network (THIN) from the UK (1993)(1994)(1995)(1996)(1997)(1998)(1999)(2000)(2001)(2002)(2003)(2004)(2005)(2006)(2007)(2008)(2009)). The eligible study cohort included individuals 18 years of age or older, with at least 1 year of THIN follow-up. The exposed group consisted of individuals with a diagnosis code for PA. The unexposed group consisted of individuals without a diagnosis of PA and was frequency matched with the exposed group with respect to age, sex, and practice site. Cox regression analysis was used to determine the hazard ratio with the 95% confidence interval for CAP associated with PA, accounting for a comprehensive list of potential confounders. Results The study included 13 605 individuals with PA and 50 586 non-PA individuals. The crude incidence rate of CAP was 9.4/1000 person-years for those with PA, versus 6.4/1000 person-years for those without PA. The multivariable adjusted hazard ratio for CAP associated with PA was 1.18 (95% confidence interval 1.08-1.29). Conclusion In this large population-based cohort study, individuals with PA and presumed chronic achlorhydria were at an increased risk for CAP. Eur
Introduction
Pernicious anemia (PA) is an autoimmune disease characterized by autoantibodies directed against gastric parietal cells [1] . This loss of gastric parietal cells leads to atrophic gastritis and subsequent achlorhydria. It has been postulated that the increase in gastric pH facilitates bacterial colonization in the stomach, which then potentially leads to colonization of the upper aerodigesitve tract with pathogens and subsequently an increased risk for pneumonia [2, 3] . To our knowledge, the relationship between PA and the risk for pneumonia has not been previously studied.
An important parallel group of patients with chronic gastric acid suppression are those who take proton-pump inhibitors (PPIs). However, existing epidemiological studies that have investigated the association between PPI therapy and the risk for community-acquired pneumonia (CAP) have yielded conflicting results [4] [5] [6] [7] [8] [9] [10] [11] .
If a true causal relationship exists between suppression of gastric acid production and CAP, then this effect should be manifested to its fullest extent in patients with PA and achlorhydria. Thus, the aim of this population-based retrospective cohort study was to determine whether patients with PA are at an increased risk of developing CAP.
Methods

Study design
We performed a retrospective cohort study using The Health Improvement Network (THIN) from the UK. Our study was approved by the University of Pennsylvania Institutional Review Board and the THIN Scientific Review Committee.
Data source
THIN is a computerized medical record database system for GPs in the UK [12] . It covers patients from over 500 general practices who are representative of the UK population by age, sex, medical conditions, and death rates adjusted for demographics and social deprivation [13, 14] . THIN contains data that are publicly available, de-identified, and without any patient identifiers. Data collected include demographic information, diagnoses, symptoms, prescriptions issued, tests and results, as well as dates of entry in and out of the database [13] . Medical diagnoses are recorded into THIN using the Read Clinical Classification version 2. Medications prescribed to patients are logged into THIN using a drug dictionary. All practices contributing data to THIN are instructed to follow a standardized protocol of entering information, and data quality is monitored through routine analysis of the entered data. Numerous prior studies have validated the high quality of the diagnoses, prescription records, and documentation in THIN [15] [16] [17] [18] [19] [20] [21] .
Study cohort
THIN from 1993 to 2009 included data from ∼ 9.5 million patients. Our study cohort consisted of all individuals who were 18 years of age or older at the start of THIN followup and who had at least 1 year of THIN follow-up. Individuals with a history of CAP before the start of THIN follow-up were excluded from the study cohort.
Exposed group
The exposed group comprised all individuals from the study cohort with a diagnosis code for PA in THIN. Start of follow-up for the exposed group was defined as the latest of the following: the date PA diagnosis was made, the Vision date, or 6 months after the THIN registration date. The registration date is defined as the date on which patients were first registered with a practice in THIN, and the Vision date is the date on which a practice began using in-practice Vision software that collects information for the THIN database. The end of the follow-up period was defined either by CAP diagnosis or by patient exit from THIN follow-up because of migration or death.
Unexposed group
All individuals in the study cohort without a diagnosis code for PA were initially considered as potentially eligible to be included in the unexposed group. We randomly selected non-PA individuals from this group to form the unexposed group by frequency matching this unexposed group with the exposed group at a 4 : 1 unexposed to exposed ratio, with respect to age at the start of THIN follow-up ( 5 years), sex, and practice site. Start of THIN follow-up for the unexposed group was defined as the latest of the following: the Vision date or 6 months after the THIN registration date. The end of the follow-up period was defined by a CAP diagnosis or by patient exit from THIN follow-up.
Outcomes and covariates
The primary outcome in our study was time to the first episode of CAP recorded during the follow-up period. The diagnosis of CAP was based on the presence of Read codes (Supplementary Table 1 , Supplemental digital content 1, http://links.lww.com/EJGH/A47). We examined a comprehensive list of potential confounders including age, sex, smoking status, and comorbidities (i.e. alcoholism, chronic obstructive pulmonary disease, asthma, hypertension, coronary artery disease, congestive heart failure, chronic renal failure, diabetes mellitus, cancer other than basal cell carcinoma, stroke, dementia, history of organ transplant, connective tissue disorder, peripheral vascular disease, cirrhosis, inflammatory bowel disease, gastroesophageal reflux disease, peptic ulcer disease, and dysphagia).
In addition, medications that were included as covariates in the model were anxiolytics, antidepressants, anti-Parkinson drugs, antipsychotics, barbiturates, opiates, corticosteroids, antibiotics, NSAIDs, PPIs, and histamine-2-receptor (H2R) antagonists. Because the potential effect of these medications on CAP risk would likely occur following a short exposure period and over a short latency period, we treated these variables as time-varying by dividing the entire follow-up period of each individual into consecutive time blocks of 2-month duration (with the last block being ≤ 2 months in duration). We then determined the exposure status of each individual for each medication in each of these 2-month blocks separately. We considered a medication as being actively used if the intended duration of the prescription for the medication was more than 50% of the duration of the entire block. Furthermore, a patient was considered to have a comorbid condition for a 2-month follow-up block if the earliest recorded date for that diagnosis in THIN was on or before the start date of the 2-month block.
Statistical analyses
All statistical analyses were carried out using Stata 13.1 (StataCorp LP, College Station, Texas, USA). A P-value of less than 0.05 was considered statistically significant in all analyses. Descriptive statistical analyses were carried out to determine the baseline characteristics of the exposed and unexposed groups. Student's t-test and the χ 2 -test were used to analyze continuous and categorical variables, respectively. The crude incidence of CAP in each group was estimated by dividing the number of incident CAP cases by the total person-years of follow-up.
We carried out a multivariable Cox regression analysis to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) for the risk for CAP in patients with and without PA, with robust estimate of variance to account for clustering due to the inclusion of time-varying covariates. Potential confounders as listed above were included in the multivariable regression model.
Sensitivity analyses
Given the potential for misclassification of PA status based on diagnostic code alone, we carried out three sensitivity analyses to increase the validity of the PA exposure definition. First, we restricted the PA group to patients with a PA diagnosis code and documented vitamin B12 therapy. Second, given that patients with true PA and achlorhydria would not be expected to be prescribed gastric acidsuppressive medications, we carried out another analysis limiting the PA group to individuals who had a PA diagnosis code, were on vitamin B12 therapy, and who had not been prescribed a PPI or H2R antagonist. Third, we further restricted the PA group to incident cases (i.e. patients diagnosed with PA at least 6 months after the start of THIN follow-up) and patients who were also on vitamin B12 therapy and had not been on acid-suppressive medications. Previous work in a similar UK database showed that the 6-month threshold was adequate for capturing incident diagnosis of chronic conditions [22] . For all sensitivity analyses, we carried out multivariable Cox regression analysis as described above to calculate HRs and 95% CIs for the risk for CAP.
Results
Study population
We identified~9.5 million patients enrolled in THIN from 1993 to 2009, among whom~8.0 million had acceptable records in THIN (Fig. 1 ). In this group, 17 433 patients had a diagnosis code for PA. We excluded 3828 PA patients as they were either younger than 18 years at the start of THIN follow-up, had less than 1 year of follow-up in THIN, or had a history of CAP before the start of THIN follow-up. Therefore, 13 605 individuals were included in our PA exposure group. A total of 50 586 non-PA patients without a CAP diagnosis before THIN follow-up were selected to form the unexposed group, which was frequency matched with the PA group with respect to sex, age at the start of follow-up, and practice site. Table 1 shows the characteristics of the study population at the start of THIN follow-up. Patients with PA were more likely to have potentially confounding medical diagnoses compared with the control group. No differences were seen in the prevalence of gastroesophageal reflux disease between the two groups. PA patients were also more likely to be taking potentially confounding medications versus non-PA patients. The mean follow-up time for the non-PA patients was slightly longer than that for the PA patients (5.5 vs. 5.2 years, P < 0.001).
Primary analyses
Overall, the crude incidence rate of CAP was higher among patients with a diagnosis of PA (9.4 cases per 1000 person-years) compared with matched controls (6.4 cases per 1000 person-years). In unadjusted Cox regression analysis, PA patients had an increased risk for CAP compared with controls (HR 1.49, 95% CI 1.37-1.63; Table 2 ). After adjusting for confounders, the HR for CAP associated with PA attenuated to 1.18 (95% CI 1.08-1.29).
Sensitivity analyses
Results from sensitivity analyses are listed in Table 3 . The analysis restricting PA patients to those with documented vitamin B12 supplementation yielded nearly identical results to the primary analysis (adjusted HR 1.17, 95% CI 1.06-1.28). Further exclusion of PA patients who received any acid-suppressant led to minimal change in the point estimate (adjusted HR 1.25, 95% CI 1.10-1.41). Finally, we limited the exposure group to patients with an incident diagnosis of PA and who were on vitamin B12 therapy but not on any acid-suppressive medication. Again, the results were largely unchanged compared with the primary analysis (adjusted HR 1.20, 95% CI 0.99-1.44).
Discussion
In this population-based retrospective cohort study, individuals with PA and presumed chronic achlorhydria had a modestly increased risk for CAP compared with those without PA, even after adjusting for confounding medications and comorbidities. This association was robust to sensitivity analyses with a more stringent definition of PA and restriction to incident PA diagnosis.
Our findings suggest that PA should be considered an independent risk factor for CAP. This increased risk is likely due in part to the PA-induced achlorhydria, which prevents formation of the 'gastric bactericidal barrier'. Loss of this barrier has been theorized to facilitate bacterial colonization in the stomach, thereby leading to possible colonization of the upper aerodigesitve tract by pathogens and to CAP [23, 24] . Supporting this theory is the finding that when 10 9 viable bacteria were inoculated into fasting stomachs of PA patients (gastric pH > 6.8), no reduction in bacterial numbers was seen after 1 h [2] . Among individuals with normal stomachs (pH <3.0), no recoverable bacteria were observed after 1 h [2] . Other investigators also found that individuals with PA had gastric and duodenal juices that grew more nitrate-reducing bacteria compared with controls [3] . An important parallel group of patients with chronic gastric acid suppression are patients who take PPIs. In a meta-analysis, Johnstone et al. [25] observed that PPI users had 36% higher odds for developing CAP compared with nonusers. However, the risk increase was limited to a short duration of PPI use, whereas longer-term PPI use did not increase CAP risk [25] . Our finding of a modest increase in the risk for CAP associated with PA is consistent with the lack of association between chronic PPI therapy and the risk for CAP. Chronic PPI use, even at high doses, generally does not lead to the same level of gastric acid suppression experienced by those with PA. The mean intragastric pH found with PPIs across different dosages ranged from 1.4 to 6.4 [26] , compared with 6.8 to 8.3 among individuals with PA [2, 27] . Moreover, whereas PA leads to chronic and persistent achlorhydria, PPIs do not result in 24-h gastric acid suppression. Prior studies have found that the intragastric pH was less than 4 for 10-14 h per day among those taking PPIs once daily [28] . Even among individuals taking PPIs twice daily, nocturnal acid breakthrough has been demonstrated [29] . Thus, even if the 'gastric bactericidal barrier' theory does have clinical relevance, the modest association that we found between PA and CAP suggests that PPIs may not increase the risk for CAP, as they cannot achieve the same level of gastric acid suppression seen with PA.
This study has limitations. First, we were not able to definitively confirm the PA diagnosis with results from Schilling tests or through intrinsic factor antibody results, as these data could not be reliably obtained. However, 95% of the patients with a PA diagnosis had vitamin B12 supplementation documented in THIN, and our results were virtually unchanged when we restricted the PA group to those with a PA diagnosis and documented vitamin B12 use. Results from our analysis that additionally excluded individuals prescribed PPIs or H2R antagonists, medicines unlikely to have been prescribed to those with true PA, were also largely unchanged compared with our primary analysis. In addition, limiting the exposed group to incident cases of PA did not significantly change the results as well. Data from these sensitivity analyses suggest that potential misclassification of PA status did not have a significant impact on our study. Moreover, any misclassification of PA status would likely be nondifferential, which would tend to bias the results toward the null. Thus, our calculated adjusted HR may be an underestimate of the true risk. Second, we did not collect information on concomitant immunodeficiencies. Limited reports have linked PA to common variable immunodeficiencies, low serum immunoglobulin concentrations, and selective IgA deficiency [30] [31] [32] [33] . Although these reports are not definitive, it is possible that some PA patients in our study had a concomitant immunodeficiency disorder, leading to an increased risk for CAP that was independent of the loss of the 'gastric bactericidal barrier'. Finally, we could not confirm the CAP diagnosis with microbiological or radiographic data, as this information was unavailable for most individuals with a CAP diagnosis code. However, CAP diagnosis codes in the General Practice Research Database, another UK computerized medical record database similar to THIN in terms of data collection and recording [18] , were found to be valid for identification of CAP [34] . In fact, a previous General Practice Research Database study used the same definition of CAP as ours and found it to capture the effect of PPI-induced acid suppression similarly to a more stringent definition of hospitalized CAP [10] .
Conclusion
In this large population-representative cohort study, we observed a modest increase in the risk for CAP among PA patients with presumed chronic achlorhydria compared with those without PA, even after adjusting for confounding comorbidities and medications. This suggests that PA should be considered an independent risk factor for CAP.
